A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
Date
2002Author
Kalofonos, H. P.Nikolaides, C.
Samantas, E.
Mylonakis, N.
Aravantinos, Gerasimos
Dimopoulos, M. A.
Gennatas, Constantinos
Kouvatseas, G.
Giannoulis, E.
Dervenis, C.
Basdanis, G.
Pavlidis, Nicholas
Androulakis, G.
Fountzilas, George
Source
American Journal of Clinical Oncology: Cancer Clinical TrialsVolume
25Issue
1Pages
23-30Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
We conducted a phase III study in patients with advanced colorectal carcinoma (ACC). The total number of patients randomized from October 1993 until July 1998 was 192, whereas therapy was started on 179 and 158 (82.3%) have been evaluable. The treatment schedules consisted of weekly bolus administration for 6 weeks of 5-fluorouracil (5-FU), 600 mg/m2 (arm I) versus 5-FU (500 mg/m2) intravenous bolus and interferon-α, 5 MU subcutaneously, three times a week (arm II) versus leucovorin 200 mg/m2 in 2-hour infusion and 5-FU 500 mg/m2 intravenous bolus at the midtime of leucovorin infusion (arm III) followed by a 2-week rest period. Treatment was continued for six cycles or until progression. This study failed to show any superiority of the modulated 5-FU versus single administration of 5-FU. There were no significant differences between the three arms in the overall response rate (10.3% versus 11.3% versus 12.9%, p = 0.95), the time to tumor progression (median, 3.9 versus 3.8 versus 6.0 months, p = 0.59), or survival duration (median, 14.7 versus 12.4 versus 16.3 months, p = 0.71). The incidence of severe (grades III and IV) toxicity was significantly higher in patients in arm II and III (24.5% and 18.6%) versus arm I (6.0%) (p = 0.01). Because modulated 5-FU failed to show superiority versus 5-FU, new agents and new strategies are needed for the treatment of advanced colorectal carcinoma.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Probing the unknown in cancer of unknown primary: Which way is the right way?
Pentheroudakis, George; Pavlidis, Nicholas (2010)
-
Article
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Golfinopoulos, Vassilis; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2007)Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...
-
Article
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...